Technology area: Biotechnology & Pharmaceuticals
49 pending office actions • 40 clients • 46 examiners • 37 art units • 0 of 49 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
ELMORE PATENT LAW GROUP, PC has 51 pending office actions in Biotechnology & Pharmaceuticals and 2871 career applications. The active docket and application history indicate a substantial life-sciences prosecution practice.
The resolved allowance rate is 73.36%, and the average office actions per allowance is 3.23. The figures pair a majority resolved allowance outcome with a measurable examination burden, giving practitioners context for both expected results and prosecution activity.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 4 (8%) |
| §103 only | 8 (16%) |
| §102 only | 1 (2%) |
| Double-patenting only | 3 (6%) |
| Double-patenting + other | 8 (16%) |
| Multi-statute (no §101) | 24 (49%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 3 | 74.8% | +15.7% |
| ANDERSON, REBECCA L | 2 | 73.3% | +23.7% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| MCLEAN, IAN SCOTT | 1 | 43.5% | +31.1% |
| BOUTSIKARIS, LEONIDAS | 1 | 84.9% | +17.2% |
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17478293 | ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY | SULLIVAN, STEPHANIE LAUREN | 73d overdue |
| 18749872 | Systems and Methods for Producing Carbon Solids | HERNANDEZ-KENNEY, JOSE | 43d overdue |
| 18505538 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | ROBINSON, MIKHAIL O'DONNEL | 5d |
| 18031902 | PROCESS FOR THE PRODUCTION OF 21-(ACETYLOXY)-17-(PROPIONYLOXY)-PREGN-4-ENE-3,20-DIONE | MOORE, SUSANNA | 5d |
| 17623331 | APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM | DAHLIN, HEATHER RAQUEL | 20d |
| 17951891 | PHASED INTRODUCTION OF LITHIUM INTO THE PRE-LITHIATED ANODE OF A LITHIUM ION ELECTROCHEMICAL CELL | CHAN, HENG M | 26d |
| 18480009 | USE AND DETECTION METHOD OF FLAVIVIRUS PROTEIN MICROARRAY | CHESTNUT, BARRY A | 28d |
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | JONES-FOSTER, ERICA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | JONES-FOSTER, ERICA NICOLE | — |
| 18989671 | Surfactant Formulations for Inhalation | HAGHIGHATIAN, MINA | — |
| 18983619 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | WHITE, DAWANNA SHAR-DAY | — |
| 18983718 | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | VAJDA, KRISTIN ANN | — |
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | — |
| 18931405 | Intelligent Computer Aided Decision Support System | MCLEAN, IAN SCOTT | — |
| 18924250 | Self-Locking Eyeglass System | BOUTSIKARIS, LEONIDAS | — |
| 18917018 | Ester Substituted Ion Channel Blockers and Methods for Use | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1624 | 4 |
| 1616 | 2 |
| 1627 | 2 |
| 1612 | 2 |
| 1615 | 2 |
| 1618 | 2 |
| 1625 | 2 |
| 1626 | 2 |
| 1643 | 2 |
| 1656 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | Endura S.p.A. | JONES-FOSTER, ERICA NICOLE | 1656 | §101§112 | Non-Final OA | — | Pending | Jan 24, 2025 |
| 18989671 | Surfactant Formulations for Inhalation | Merz Pharmaceuticals, LLC | HAGHIGHATIAN, MINA | 1616 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18983619 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | Alkermes, Inc. | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103DP | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18983718 | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | Alkermes, Inc. | VAJDA, KRISTIN ANN | 1622 | §101 | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18958046 | Compositions and Methods for Cancer Immunotherapy | The UAB Research Foundation | POPA, ILEANA | 1633 | §103§112Other | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18931405 | Intelligent Computer Aided Decision Support System | Corti Aps | MCLEAN, IAN SCOTT | 2654 | §103 | Non-Final OA | — | Pending | Oct 30, 2024 |
| 18924250 | Self-Locking Eyeglass System | Lindberg A/S | BOUTSIKARIS, LEONIDAS | 2872 | §102§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18917018 | Ester Substituted Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §102§103§112Other | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18905381 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §102§112Other | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18899798 | METHODS FOR TREATMENT OF DISEASES | Serpin Pharma, LLC | MARTINEZ, TARA L | 1654 | DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18899325 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | COLEMAN, BRENDA LIBBY | 1624 | §102§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18851368 | High Concentration H2 Aqueous Solution And Its Use | Blue Hydrogen Science S.R.L | COHEN, MICHAEL P | 1612 | §103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18804359 | Engine Systems and Uses Thereof | Alpha Portfollo LLC | MEADE, LORNE EDWARD | 3741 | §103 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18802537 | Processes for Producing Reactant Chemical Substances for Thermal Devices | Aipha Portfolio Llc. | SAVANI, AVINASH A | 3762 | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18722843 | NOVEL ANTIVIRAL COMPOSITIONS COMPRISING OLEIC ACID | Subintro Limited | NGUYEN, NGOC-ANH THI | 1615 | §102§103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18749872 | Systems and Methods for Producing Carbon Solids | Soane Labs, LLC | HERNANDEZ-KENNEY, JOSE | 1717 | §103§112 | Final Rejection | 43d overdue | Pending | Jun 21, 2024 |
| 18718625 | Cosmetic Composition For Restructuring Hair And Improving The Appearance Thereof | Giuliani S.p.A. | WEBB, WALTER E | 1612 | DP | Final Rejection | — | Pending | Jun 11, 2024 |
| 18675346 | RADIOPHARMACEUTICAL TREATMENT METHODS AND USE | Point Biopharma, Inc. | JONES, DAMERON LEVEST | 1618 | §103§112Other | Non-Final OA | — | Pending | May 28, 2024 |
| 18663301 | Method for Producing Hydrogels | Gelesis, LLC | OLSON, ANDREA STEFFEL | 1693 | §102§112Other | Non-Final OA | — | Pending | May 14, 2024 |
| 18659478 | Compositions and Methods for Modulating the Intestinal Microbiome | Gelesis S.R.I. | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | May 09, 2024 |
| 18652015 | Monomethylfumarate Prodrug Compositions | Alkermes Pharma Ireland Limited | SAEED, ALI S | 1616 | §103 | Non-Final OA | 26d | Pending | May 01, 2024 |
| 18644859 | Systems and Methods for Processing Gases | Transform Materials LLC | PARSA, JAFAR F | 1692 | DP | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18428068 | SINGLE WALLED CARBON NANOTUBE-BASED SLURRY FOR IMPROVED NUCLEAR FUEL CLADDING COATINGS AND METHOD OF FABRICATION OF SAME | Atomic Energy Of Canada Limited/Ènergie Atomique Du Canada Limitèe | NASSIRI MOTLAGH, ANITA | 1734 | §103§112 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18578962 | Phytase Variants | AB Enzymes Finland OY | ESSEX, LAURA ANN | §102§103§112Other | Non-Final OA | — | Pending | Jan 12, 2024 | |
| 18406738 | CARBOXYLIC ACID PLATFORM FOR FUEL AND CHEMICAL PRODUCTION AT HIGH CARBON AND ENERGY EFFICIENCY | Mojia Biotech Pte. Ltd. | STANKOVIC, BRATISLAV | 1662 | §103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18391989 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | Beyond Air Ltd. | DIXON, ANNETTE FREDRICKA | 3785 | §102§112DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18569713 | Complexes Of CU(I) As Antitumor Agents | UNIVERSITA DEGLI STUDI DI PADOVA | CHANDRAKUMAR, NIZAL S | 1625 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. | KOSAR, ANDREW D | 1625 | §102 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18505538 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112Other | Final Rejection | 5d | Pending | Nov 09, 2023 |
| 18480009 | USE AND DETECTION METHOD OF FLAVIVIRUS PROTEIN MICROARRAY | National Cheng Kung University | CHESTNUT, BARRY A | 1672 | §101§103§112 | Non-Final OA | 28d | Pending | Oct 03, 2023 |
| 18454013 | PEPTIDES AND METHODS OF USING THE SAME | Serpin Pharma, LLC | FISCHER, JOSEPH | 1658 | §102§103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18226984 | BIOMARKERS FOR FIMEPINOSTAT THERAPY | Curis, Inc. | SMITH, JENNIFER JOY | 1685 | §101§103§112 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18327321 | ITERATIVE PLATFORM FOR THE SYNTHESIS OF ALPHA FUNCTIONALIZED PRODUCTS | Ramon Gonzalez | HUTSON, RICHARD G | 1652 | §112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18253712 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | Dunad Therapeutics Ltd. | ANDERSON, REBECCA L | 1626 | §102§112 | Non-Final OA | — | Pending | May 19, 2023 |
| 18035623 | PHOTOSTABLE COMPOSITION | Ndg Natural Development Group S.r.l. | BROWE, DAVID | 1617 | §103§112 | Final Rejection | — | Pending | May 05, 2023 |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | Enanta Pharmaceuticals, Inc. | ANDERSON, REBECCA L | 1626 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18031902 | PROCESS FOR THE PRODUCTION OF 21-(ACETYLOXY)-17-(PROPIONYLOXY)-PREGN-4-ENE-3,20-DIONE | Industriale Chimica S.r.l. | MOORE, SUSANNA | 1624 | §103§112 | Non-Final OA | 5d | Pending | Apr 14, 2023 |
| 18032023 | A Purified Extract Isolated from Agrimonia Coreana Nakai Containing Abundant Amount of Active Ingredient, the Preparation Thereof, the Composition Comprising the Same as an Active Ingredient for Preventing or Treating Inflammation, Allergy and Atopic Dermatitis and the Use Thereof | Yuran Nam | MOREAU, NASHARA LOUISE | 1655 | §101§102§112 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18161405 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | Angiex, Inc. | VAN DRUFF, SYDNEY | 1643 | §102§103Other | Final Rejection | — | Pending | Jan 30, 2023 |
| 18080114 | Systems And Methods For Carbon Dioxide Conversion | Carbogenesis LLC | TAI, XIUYU | 1795 | §102§103 | Non-Final OA | — | Pending | Dec 13, 2022 |
| 17981620 | Methods and Compositions for Weight Management and for Improving Glycemic Control | Gelesis, LLC | LI, CHANGQING | 1791 | §103 | Non-Final OA | 63d | Pending | Nov 07, 2022 |
| 18051573 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | Angiex, Inc. | SKOKO III, JOHN JOSEPH | 1643 | §102§103 | Non-Final OA | — | Pending | Nov 01, 2022 |
| 17951891 | PHASED INTRODUCTION OF LITHIUM INTO THE PRE-LITHIATED ANODE OF A LITHIUM ION ELECTROCHEMICAL CELL | Nanoscale Components, Inc. | CHAN, HENG M | 1725 | §103§112 | Final Rejection | 26d | Pending | Sep 23, 2022 |
| 17934450 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. | PERREIRA, MELISSA JEAN | 1618 | §103DP | Non-Final OA | — | Pending | Sep 22, 2022 |
| 17892436 | SURFACTANT FORMULATIONS FOR INHALATION | Merz Pharmaceuticals, LLC | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | 98d overdue | Pending | Aug 22, 2022 |
| 17697081 | COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING | Arnay Sciences, LLC | TRAN, CHRISTINA L | 1637 | §103 | Non-Final OA | — | Pending | Mar 17, 2022 |
| 17623331 | APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM | Shenzhen Evergreen Therapeutics Co., Ltd. | DAHLIN, HEATHER RAQUEL | 1629 | §103§112 | Final Rejection | 20d | Pending | Dec 28, 2021 |
| 17478293 | ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY | Arnay Sciences LLC | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Final Rejection | 73d overdue | Pending | Sep 17, 2021 |
| 16755370 | METHOD FOR SELECTING HIGHLY EFFICIENT STEM CELL, USING PROTEIN MARKER GRP78 | Seoul National University R&Db Foundation | SZPERKA, MICHAEL EDWARD | 1641 | §103 | Non-Final OA | — | Pending | Apr 10, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial73.4% of resolved applications prosecuted by Elmore Patent Law Group, Pc were allowed, across 2,871 applications in USPTO records.
3.23 office actions per allowed application on average.
49 pending office actions as of October 2026, for 40 clients, before 46 examiners in 37 art units.
